While JAK2 inhibitor resistance at molecular level is ill-defined, there is increasing evidence that ruxolitinib treatment persistence in MPN patients may be due to non-JAK2 mutations, such as activating mutations of RAS, MEK and AKT (58). The gene discussed is JAK2; the disease is myeloproliferative disorder.